Pharmacogenomics Market to Top $10.26 Billion By 2025

The global pharmacogenomics market garnered $5.3 billion in 2017, and is expected to reach $10.2 billion by 2025, registering a CAGR of 8.6% from 2018 to 2025.

Increasing demand for personalized therapy, growing prevalence of life-threatening diseases worldwide, and technological advancements in the molecular techniques used for pharmacogenomics-based diagnostics have fueled the growth of the global pharmacogenomics market. On the other hand, lack of well-trained as well as technically skilled professionals and complexities in finding the right gene affecting the drug response have happened to curb the growth to some extent. However, technological advancements in molecular techniques used for pharmacogenomics diagnostic tests have created lucrative opportunities in the segment.

Request Sample Report at
https://www.alliedmarketresearch.com/request-sample/5220

Polymerase chain reaction to maintain its dominance during the forecast period-

By technology, polymerase chain reaction accounted for two-fifth of the total market in 2017 and have come out as the lion shareholder. The fact that polymerase chain reaction is the one of the most commonly used technologies used during the pharmacogenomics diagnostic tests has spurred the growth. Also, its edge over other molecular diagnostic tools in amplifying the sample DNA has coaled the growth.

Oncology Segment to maintain its top status till 2025-

By application, the oncology segment contributed to more than one-third of the total market in 2017 and is anticipated to dominate by 2025. This is due to the prevalence of cancer with lack of proper drugs at disposal and chances of relapse. Pharmacogenomics is used in the development of personalized therapy which will be able to provide personalized therapy to the patients suffering from this deadly disease.

Hospitals and clinics segment to be dominant through 2018-2025-

Based on end-user, hospitals and clinics held the major share, accounting for more than two-third of the total market in 2017. This is due to the presence of technologically advanced diagnostic equipment and highly skilled health care professionals.

North America to have the major share-

Based on geography, North America contributed to two-fifth of the total market share in 2017. Higher disposable income group, better infrastructure, high-end healthcare facilities, and several government based initiatives for the welfare of the citizens have propelled the growth of pharmacogenomics market in the region.

For Purchase Enquiry at https://www.alliedmarketresearch.com/purchase-enquiry/5220

Key players in the industry-

Leading market players analyzed in the research include
o Dynamic DNA Laboratories,
o Empire Genomics, LLC,
o Illumina, Inc.,
o Thermo Fisher Scientific, Inc.,
o Abbott Laboratories,
o OneOme LLC,
o Myriad Genetics Inc.,
o OPKO Health, Inc. (GeneDx),
o F. Hoffmann-La Roche Ltd.

They have adopted a plethora of strategies to maintain their top status in the industry. The other players mentioned in the report include Bayer AG, Teva Pharmaceutical Industries Ltd., and Assurex Health Inc.

Table Of Content

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growing demand for personalized therapy
3.4.1.2. Increased prevalence of life-threatening diseases worldwide
3.4.1.3. Technological advancements in the molecular techniques used for pharmacogenomics-based diagnostics
3.4.2. Restraints
3.4.2.1. Dearth of well-trained and technically skilled professionals
3.4.2.2. Complexities in finding the right gene affecting the drug response
3.4.3. Opportunity
3.4.3.1. Technological advancements in molecular techniques used for pharmacogenomics diagnostic tests
3.4.3.2. Lucrative opportunities in the emerging economies
3.5. Top Player Positioning, 2017....

Related Report:

Disposable Medical Supplies Market to Touch $80.25 Billion By 2023
https://www.medgadget.com/2019/01/disposable-medical-supplies-market-value-is-looking-to-raise-up-to-80252-million-worldwide-by-2017-2023.html

STD Testing Market To Hit $133.9 Billion By 2025
https://www.medgadget.com/2019/10/std-testing-market-value-to-cross-133-9-billion-by-2025.html

Biopsy Devices market to Top $4.31 Bn by 2026, at 5.9% CAGR
https://www.medgadget.com/2020/01/biopsy-devices-market-to-top-4-31-bn-by-2026-at-5-9-cagr.html

Top 6 Things to Know About $98.73 Billion Surgical Robotics Market
https://www.medgadget.com/2018/12/surgical-robotics-market-study-on-key-players-and-their-strategies-to-analyzed-the-competitive-outlook-of-global-industry.html

Drug Abuse Testing Market To Hit $11.83 Billion By 2025
https://www.medgadget.com/2019/01/global-drug-abuse-testing-market-is-expected-to-grow-at-a-considerable-cagr-by-2025-amr.html

Access Full Summery @ https://www.alliedmarketresearch.com/pharmacogenomics-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.